|
TORONTO, ON / ACCESSWIRE / November 22, 2022 / Canntab Therapeutics Limited CSE:PILLOTCQB:CTABFFRA:TBF1 the "Company" or "Canntab" a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is providing an update on several matters impacting the Company.Over the past number of months, Canntab has undertaken a strategic review of its... Lire le communiqué |
